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Introduction
Hyperhomocysteinemia is a common, independent
risk factor for cardiovascular disease (1–9). Up to 40%
of patients diagnosed with premature coronary artery,
cerebrovascular, or peripheral vascular disease are
reported to have hyperhomocysteinemia. Patients
with severe hyperhomocysteinemia due to cystathio-
nine β-synthase (CBS) deficiency also exhibit a wide
range of clinical manifestations, including athero-
sclerosis, thrombosis, mental retardation, ectopia
lentis, osteoporosis, and skeletal abnormalities. These
patients also develop hepatic steatosis or “fatty liver,”
which is characterized by enlarged, multinucleated
hepatocytes containing microvesicular lipid droplets
(10, 11). Consistent with these findings, homozygous
CBS-deficient mice having severe hyperhomocys-
teinemia also develop hepatic steatosis (12).
Several mechanisms have been proposed to explain
the pathological changes associated with hyperhomo-
cysteinemia. Homocysteine has been shown to cause
cell injury when administered to animals (13, 14) or
when added directly to cultured mammalian cells
(15–17). Furthermore, cultured vascular endothelial
cells from patients with heterozygous CBS deficiency
are more sensitive to homocysteine-induced damage
than are wild-type cells (17). Because homocysteine is
generated intracellularly and can accumulate in cells
(18, 19), it has been suggested that homocysteine
could act intracellularly to directly modulate the activ-
ity of both large (enzymes, receptors) and small mole-
cules (nitric oxide, glutathione) (20).
We have reported that homocysteine causes protein
misfolding in the endoplasmic reticulum (ER) and acti-
vates the unfolded protein response (UPR), leading to
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Hepatic steatosis is common in patients having severe hyperhomocysteinemia due to deficiency for
cystathionine β-synthase. However, the mechanism by which homocysteine promotes the develop-
ment and progression of hepatic steatosis is unknown. We report here that homocysteine-induced
endoplasmic reticulum (ER) stress activates both the unfolded protein response and the sterol regu-
latory element–binding proteins (SREBPs) in cultured human hepatocytes as well as vascular
endothelial and aortic smooth muscle cells. Activation of the SREBPs is associated with increased
expression of genes responsible for cholesterol/triglyceride biosynthesis and uptake and with intra-
cellular accumulation of cholesterol. Homocysteine-induced gene expression was inhibited by over-
expression of the ER chaperone, GRP78/BiP, thus demonstrating a direct role of ER stress in the acti-
vation of cholesterol/triglyceride biosynthesis. Consistent with these in vitro findings, cholesterol
and triglycerides were significantly elevated in the livers, but not plasmas, of mice having diet-induced
hyperhomocysteinemia. This effect was not due to impaired hepatic export of lipids because secre-
tion of VLDL-triglyceride was increased in hyperhomocysteinemic mice. These findings suggest a
mechanism by which homocysteine-induced ER stress causes dysregulation of the endogenous sterol
response pathway, leading to increased hepatic biosynthesis and uptake of cholesterol and triglyc-
erides. Furthermore, this mechanism likely explains the development and progression of hepatic
steatosis and possibly atherosclerotic lesions observed in hyperhomocysteinemia.
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increased expression of the ER stress-response genes,
GRP78/BiP and GADD153 (21, 22). These observa-
tions suggest that homocysteine acts intracellularly to
cause cell dysfunction by perturbing the ER. Consistent
with our findings, another group has also demonstrat-
ed that homocysteine activates the UPR in cultured
vascular endothelial cells, leading to increased expres-
sion of GRP78/BiP as well as two novel ER stress-
response genes, RTP and Herp (23, 24). However, the
mechanism by which the ER stress-inducing effects of
homocysteine contribute to the pathophysiology of
hyperhomocysteinemia has not been established.
An association between UPR activation and lipid
biosynthesis has been demonstrated in yeast (25, 26)
and human fibroblasts (27). In concordance with these
studies, we have demonstrated in cultured human vas-
cular endothelial cells that homocysteine increases
expression of the sterol regulatory element–binding
protein-1 (SREBP-1) (21), an ER membrane-bound
transcription factor that functions to activate genes
encoding enzymes in the cholesterol/triglyceride
biosynthesis and uptake pathways (28, 29). However, it
is unknown whether homocysteine alters the expression
of SREBP-dependent genes that are involved in choles-
terol/triglyceride biosynthesis or whether this effect of
homocysteine influences lipid metabolism in vivo.
In this study, we used cultured human cells and
murine models of hyperhomocysteinemia to test the
hypothesis that homocysteine-induced ER stress alters
cholesterol/triglyceride metabolism. Our results show
that activation of the UPR by homocysteine induces
SREBP-dependent genes that are essential for biosyn-
thesis and uptake of cholesterol and triglycerides and
leads to the accumulation of cholesterol in cultured
cells. Furthermore, a significant increase in the levels of
cholesterol and triglycerides were observed in the livers,
but not plasmas, of hyperhomocysteinemic mice.
These results indicate that homocysteine-induced ER
stress leads to the transcriptional activation of genes
responsible for lipogenesis that likely contribute to
hepatic steatosis in hyperhomocysteinemia.
Methods
Cell culture and treatment conditions. Primary human
umbilical vein endothelial cells (HUVECs) were isolat-
ed by collagenase treatment of human umbilical veins
(30) and cultured in M199 medium (Life Technologies
Inc., Burlington, Ontario, Canada) containing 20
µg/ml endothelial cell growth factor, 90 µg/ml porcine
intestinal heparin, 100 µg/ml penicillin, 100 µg/ml
streptomycin, and 20% FBS (HyClone Laboratories,
Logan, Utah, USA). Cells from passages two to four
were used in these studies. Human aortic smooth mus-
cle cells (HASMCs) were purchased from Cascade Bio-
logics (Portland, Oregon, USA) and cultured in M231
media (Cascade Biologics) containing smooth muscle
cell growth supplement (Cascade Biologics). The
human hepatocarcinoma cell line, HepG2, was
obtained from the American Type Culture Collection
(ATCC; Rockville, Maryland, USA) and cultured in α-
DMEM (Life Technologies Inc.) containing 10% FBS.
The human transitional bladder carcinoma cell line,
T24/83, was obtained from ATCC and cultured in
M199 medium containing 10% FBS. All cells were
maintained in a humidified incubator at 37°C with 5%
CO2. DL-Homocysteine, L-methionine, DL-cysteine,
glycine, DTT, tunicamycin, A23187, and β-mercap-
toethanol were purchased from Sigma Chemical Co.
(St. Louis, Missouri, USA). These compounds were pre-
pared fresh in culture medium, sterilized by filtration,
and added to the cell cultures.
Determination of intracellular levels of homocysteine.
HepG2 cells exposed to 1 or 5 mM homocysteine for 0
to 24 hours were washed three times in α-DMEM and
three times in PBS. Cells were lysed in water by three
freeze/thaw cycles and cellular debris removed by cen-
trifugation. Total homocysteine, defined as the total
concentration of homocysteine after quantitative
reductive cleavage of all disulfide bonds (31), was deter-
mined in cellular lysates using the IMx System (Abbott
Laboratories, Mississauga, Ontario, Canada) and nor-
malized to total protein concentration.
Animals and diets. Wild-type C57BL/6 mice (CBS+/+)
were obtained from Charles River (Montreal, Québec,
Canada) or The Jackson Laboratory (Bar Harbor,
Maine, USA). Heterozygous CBS-deficient mice (CBS+/–)
(12) were crossbred to CBS+/+ mice. Genotyping for the
targeted allele was performed by PCR (12). At the time
of weaning, offspring were fed one of four diets: (a) a
control diet that contained 4.1 g L-methionine/kg and
7.5 mg folate/kg (LM-485; Harlan Teklad Laboratory,
Madison, Wisconsin, USA); (b) a high-methionine diet
that was identical to the control diet except that the
drinking water was supplemented with 0.5% L-methio-
nine; (c) a high-methionine/low-folate diet that con-
tained 1.5 mg folate/kg and drinking water that was
supplemented with 0.5% L-methionine; or (d) a very
high-methionine (24.6 g/kg), low-folate (1.5 g/kg) diet
(TD98272; Harlan Teklad Laboratory) (32). Succinyl-
sulfathiazole (1.0 mg/kg) was added to the low-folate
diets. After 2 to 20 weeks on an experimental diet, mice
were sacrificed with an intraperitoneal injection of 75
mg sodium pentobarbital, plasma was collected in
EDTA (final concentration 5–10 mM) for measure-
ment of total homocysteine, and their tissues removed
and snap-frozen in liquid N2 before storage at –70°C.
Plasma total homocysteine was measured by HPLC and
electrochemical detection as described previously (33).
The experimental protocols were approved by the Uni-
versity of Iowa and Veterans Affairs Animal Care and
Use Committees or the McMaster University Animal
Research Ethics Board.
Hepatic VLDL-triglyceride secretion rate. CBS+/+ mice fed
control or hyperhomocysteinemic diets for 2 weeks
were fasted overnight and hepatic VLDL-triglyceride
secretion rates quantified by the intravenous adminis-
tration of Triton WR1339 (500 mg/kg body weight;
Sigma Chemical Co.) as described previously (34).
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Blood samples (50 µl) were taken at 0, 2, and 4 hours
after Triton WR1339 injection, and plasma cholesterol
and triglycerides were measured enzymatically as
described below. Hepatic cholesterol and triglyceride
secretion rates were calculated from the slope of the
curve and expressed as micromole per hour per kilo-
gram of body weight.
Histological analysis. Liver tissue from mice fed control
or hyperhomocysteinemic diets for 16 to 20 weeks was
fixed in 4% formalin, embedded in paraffin, and tissue
sections were stained with hematoxylin and eosin, as
described previously (35).
Preparation of total RNA. Total RNA was isolated from
cultured cells or tissues using the RNeasy total RNA kit
(QIAGEN Inc., Mississauga, Ontario, Canada) and
resuspended in diethyl pyrocarbonate–treated water.
Quantification and purity of the RNA was assessed by
A260/A280 absorption, and RNA samples with ratios
above 1.6 were stored at –70°C for further analysis.
Northern blot analysis. Total RNA (10 µg/lane) was size
fractionated on 2.2 M formaldehyde/1.2% agarose gels,
transferred to Zeta-Probe GT nylon membranes (Bio-
Rad Laboratories Inc., Mississauga, Ontario, Canada),
and hybridized using radiolabeled cDNA probes as
described previously (21, 22). Signal intensities were
quantified by densitometric scanning of the autoradi-
ograms using the ImageMaster VDS and Analysis Soft-
ware (Amersham Pharmacia Biotech, Baie d’Urfé,
Québec, Canada). To correct for differences in gel load-
ing, integrated optical densities were normalized to
human GAPDH. The human isopentenyl diphos-
phate:dimethylallyl diphosphate (IPP) isomerase cDNA
encodes an 837-bp DNA fragment from the 3′-untrans-
lated region of the IPP isomerase gene. The cDNA
probes encoding human 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase and farnesyl
diphosphate (FPP) synthase were kindly provided by
Skaidrite Krisans (San Diego State University, San
Diego, California, USA). Human SREBP-1 cDNA
(number AA568572) was purchased from Genome Sys-
tems (St. Louis, Missouri, USA), and LDL receptor
cDNA was purchased from ATCC. The cDNA probes
encoding GRP78/BiP or GADD153 have been
described previously (21, 22).
Construction of mammalian expression plasmid encoding
human GRP78/BiP. The cDNA encoding the open read-
ing frame of human GRP78/BiP (approximately 1.95
kb) was amplified by RT-PCR using total RNA from
primary HUVECs. Primers used for RT-PCR were syn-
thesized at the Institute for Molecular Biology,
McMaster University. GRP78/BiP cDNA was generat-
ed using SuperScript RNase H– reverse transcriptase
(Life Technologies Inc.) and a primer complimentary
to a sequence in the 3′-untranslated region of the
human GRP78/BiP mRNA transcript (AB10230: 5′-
TAT TAC AGC ACT AGC AGA TCA GTG-3′). For PCR
amplification, the forward primer AB10231 (5′-CTT
AAG CTT GCC ACC ATG AAG CTC TCC CTG GTG
GCC GCG-3′) contained a Kozak consensus sequence
(boldface) prior to the initiating ATG and a terminal
HindIII restriction site (underlined). The reverse
primer AB10232 (5′-AGG CCT CGAG CT ACA ACT
CAT CTT TTT CTG CTG T-3′) contained a terminal
XhoI restriction site (underlined) adjacent to the
authentic termination codon of the GRP78/BiP
cDNA. After PCR was performed, the amplified
GRP78/BiP cDNA was gel-purified using the QIAEX
gel extraction kit (QIAGEN Inc.) and ligated into T-
ended pBluescript KS (Stratagene, La Jolla, California,
USA). The ligation mixture was then used to trans-
form competent DH5α cells (Life Technologies Inc.).
Plasmid DNA was isolated from transformed cells
using the QIAEX miniprep kit (QIAGEN Inc.), digest-
ed with HindIII and XhoI, and the GRP78/BiP cDNA
purified from agarose, as described above. The
GRP78/BiP cDNA was ligated into the HindIII/XhoI
site of the mammalian expression vector pcDNA3.1(+)
(Invitrogen Corp., Carlsbad, California, USA) to pro-
duce the recombinant plasmid, pcDNA3.1(+)-
GRP78/BiP. Authenticity of the human GRP78/BiP
cDNA sequence was confirmed by fluorescence-based
double-stranded DNA sequencing.
Establishment of stable T24/83 cell lines overexpressing
GRP78/BiP. T24/83 cells grown to 30% confluence
were transfected with 5 µg of the pcDNA3.1(+)-
GRP78/BiP expression plasmid using 30 µl of Super-
Fect transfection reagent (QIAGEN Inc.), as described
by the manufacturer. As a vector control, T24/83 cells
were transfected with pcDNA3.1(+) under the same
conditions. Stable transfectants were selected in com-
plete medium containing 1.2 mg/ml G418 (Life Tech-
nologies Inc.) for 2 weeks. G418-resistant clones were
subsequently isolated and cultured in complete medi-
um containing 1.0 mg/ml G418. Overexpression of
GRP78/BiP was assessed using immunoblotting and
indirect immunofluorescence, as described below.
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Figure 1
Intracellular homocysteine levels in HepG2 cells. HepG2 cells were
cultured in the absence or presence of 1 mM (circles) or 5 mM (tri-
angles) homocysteine for the indicated time periods, washed, and
lysed by three freeze/thaw cycles. Total intracellular homocysteine
was determined and normalized to total protein. Data are present-
ed as the mean ± SD of three separate experiments.
Immunoblot analysis. The anti-KDEL mAb (SPA-
827), which recognizes both GRP78/BiP and
GRP94, was purchased from StressGen Biotech-
nologies Corp. (Victoria, British Columbia, Cana-
da). The anti-GADD153 polyclonal Ab (sc-575) was
purchased from Santa Cruz Biotechnology Inc.
(Santa Cruz, California, USA). The mAb’s reactive
against human SREBP-1 or -2 (clones IgG-2A4 and
IgG-1C6, respectively) were purchased from
PharMingen (Mississauga, Ontario, Canada). Total
protein lysates from mouse tissues or cultured cells
were solubilized in SDS-PAGE sample buffer and
separated on SDS-polyacrylamide gels under reduc-
ing conditions, as described previously (21, 22).
After incubation with the appropriate primary and
horseradish peroxidase-conjugated (HRP-conjugat-
ed) secondary Ab’s (Life Technologies Inc.), the
membranes were developed using the SuperSignal
chemiluminescent substrate (Pierce Chemical Co.,
Rockford, Illinois, USA).
Immunohistochemistry and image analysis. Immunohis-
tochemistry using polyclonal Ab’s against GRP78/BiP
(sc-1050; Santa Cruz Biotechnology Inc.) was per-
formed as described previously (21, 22). Images were
captured with Northern Eclipse image
analysis/archival software (Empix Imaging Inc., Mis-
sissauga, Ontario, Canada).
Uptake of BODIPY FL LDL. Cells treated in the
absence or presence of homocysteine were washed
with PBS and incubated in media containing 10
µg/ml BODIPY FL LDL (Molecular Probes, Eugene,
Oregon, USA). After incubation at 37°C for 2 hours,
cells were washed with PBS, fixed in 3% formaldehyde
in PBS, and the uptake of LDL was detected by fluo-
rescence microscopy.
Total cholesterol and triglyceride levels. Cultured cells or
tissues were homogenized in lysis buffer containing
0.1% Triton X-100. Lysates were saponified, and lipids
were extracted with hexane/isopropanol (3:2) (36). Col-
orimetric cholesterol and triglyceride assays were car-
ried out using the Sigma Diagnostics Cholesterol and
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Figure 2
Homocysteine induces the expression of GRP78/BiP and GADD153 in HepG2
cells. (a) Northern blot analysis of the steady-state mRNA levels of GRP78/BiP
and GADD153 in HepG2 cells cultured for 4 hours in the absence (control) or
presence of either 5 mM homocysteine, 5 mM cysteine, 5 mM methionine, 10
µg/ml tunicamycin, 2.5 mM DTT, 5 mM homoserine, or 5 mM glycine. Total
RNA (10 µg/lane) was size fractionated by agarose-gel electrophoresis, trans-
ferred to nylon membranes, and subjected to blot hybridization using radiola-
beled cDNA probes encoding human GRP78/BiP or GADD153. Control for
equivalent RNA loading was assessed using a radiolabeled GAPDH cDNA
probe. (b) Immunoblot analysis of GRP78/BiP and GADD153 protein in
HepG2 cells cultured in the absence or presence of 5 mM homocysteine for the
indicated time periods. HepG2 cells were also treated with 2.5 mM DTT or 10
µg/ml tunicamycin for 8 hours. Total protein lysates (40 µg/lane) were sepa-
rated on 12% SDS-polyacrylamide gels under reducing conditions, transferred
to nitrocellulose membranes and immunostained with Ab’s against either
GRP78/BiP (anti-KDEL) or GADD153.
Figure 3
Homocysteine induces the expression of SREBP-1 in HepG2 cells. (a) Immunoblot
analysis of SREBP-1 protein in HepG2 cells cultured in the absence or presence of 5
mM homocysteine for the indicated time periods. Total protein lysates (40 µg/lane)
were separated on 10% SDS-polyacrylamide gels under reducing conditions, trans-
ferred to nitrocellulose membranes, and immunostained with an mAb that recog-
nizes both the precursor (P) and mature (M) forms of SREBP-1. (b) Northern blot
analysis of the steady-state mRNA levels of SREBP-1 in HepG2 cells cultured in the
presence of 5 mM homocysteine for the indicated time periods. Total RNA (10
µg/lane) was size fractionated by agarose-gel electrophoresis, transferred to nylon
membranes, and subjected to blot hybridization using a radiolabeled cDNA probe
encoding human SREBP-1. Control for equivalent RNA loading was assessed using
a radiolabeled GAPDH cDNA probe.
Triglyceride Reagents (Sigma Chemical Co.). Total plas-
ma cholesterol and triglycerides were measured using
the same assays, but without the lipid-extraction step.
Statistical analysis. Results are presented as the mean
plus or minus SD. Differences in treatment groups
were analyzed using two-way ANOVA. On finding sig-
nificance with ANOVA, unpaired Student’s t test was
performed. For all analyses, P values less than 0.05 were
considered statistically significant.
Results
Intracellular levels of homocysteine in HepG2 cells. We have
demonstrated previously that intracellular levels of
homocysteine are transiently increased in HUVECs
exposed to exogenous homocysteine (22). To increase
intracellular homocysteine levels in HepG2 cells, vary-
ing concentrations of DL-homocysteine up to 5 mM
were added to the cell cultures. Figure 1 shows that to
attain a twofold to sixfold transient increase in intra-
cellular homocysteine, HepG2 cells require an extracel-
lular homocysteine concentration of 1 to 5 mM. These
extracellular homocysteine concentrations did not
affect overall cell number or viability as determined by
trypan blue and 51Cr-release assays (data not shown).
Homocysteine causes ER stress in HepG2 cells. We have
shown in HUVECs that homocysteine causes ER stress,
leading to activation of the UPR and increased expres-
sion of GRP78/BiP and GADD153 (21, 22). As shown
in Figure 2a, homocysteine increased the steady-state
mRNA levels of GRP78/BiP (6.7-fold) and GADD153
(3.4-fold) in HepG2 cells (P < 0.05). This effect was
selective for homocysteine because other structurally
related amino acids such as methionine, cysteine,
homoserine, and glycine did not significantly induce
the expression of these genes. In addition to homocys-
teine, other agents known to cause ER stress, including
DTT and tunicamycin, increased the steady-state
mRNA levels of GRP78/BiP and GADD153 in HepG2
cells (P < 0.05). Consistent with these findings,
GRP78/BiP and GADD153 protein levels were also ele-
vated in HepG2 cells after treatment with homocys-
teine, tunicamycin, or DTT (Figure 2b).
Induction of ER stress by homocysteine increases the expres-
sion of SREBPs and genes encoding enzymes in the choles-
terol/triglyceride biosynthetic pathway. Immunoblot analy-
sis showed that HepG2 cells had increased levels of both
mature (68 kDa) and precursor (125 kDa) forms of
SREBP-1 after treatment with homocysteine for 2 and
4 hours (Figure 3a). Mature and precursor forms of
SREBP-2 were also increased in HepG2 cells by homo-
cysteine (data not shown). Because activated SREBPs
induce (autoregulate) expression of precursor SREBPs,
in addition to regulating genes involved in choles-
terol/triglyceride biosynthesis and uptake (28, 29, 37,
38), Northern blots were used to examine the effect of
homocysteine on the steady-state mRNA levels of
SREBP-1 and several genes encoding key enzymatic
components of the cholesterol/triglyceride biosynthet-
ic pathway. Steady-state mRNA levels of SREBP-1 were
increased and peaked between 2 and 4 hours after
treatment with homocysteine (Figure 3b). Furthermore,
steady-state mRNA levels of genes encoding enzymes of
the cholesterol biosynthetic pathway, including HMG-
CoA reductase, IPP isomerase, and FPP synthase, were
increased and peaked between 2 and 4 hours in HepG2
cells after treatment with homocysteine (Figure 4).
Steady-state mRNA levels for the LDL receptor, as well
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Figure 4
Homocysteine induces the steady-state mRNA levels of genes involved
in cholesterol biosynthesis in HepG2 cells. Northern blot analysis of
the steady-state mRNA levels of IPP isomerase, HMG-CoA reductase,
and FPP synthase in HepG2 cells cultured in the absence or presence
of 5 mM homocysteine for the indicated time periods. Total RNA (10
µg/lane) was size fractionated by agarose-gel electrophoresis, trans-
ferred to nylon membranes, and subjected to blot hybridization using
the appropriate radiolabeled cDNA probe. Control for equivalent RNA
loading was assessed using a radiolabeled GAPDH cDNA probe.
Figure 5
Effect of ER stress agents on steady-state mRNA levels of IPP iso-
merase in HepG2 cells. Equivalent amounts of total RNA (10 µg/lane)
isolated from HepG2 cells cultured for 4 hours in the absence (con-
trol) or presence of 5 mM homocysteine, 2.5 mM DTT, 5 mM β-mer-
captoethanol, 10 µM of the Ca2+ ionophore A23187, or 10 µg/ml
tunicamycin were examined by Northern blot analysis using a radio-
labeled IPP isomerase cDNA probe. Control for equivalent RNA load-
ing was assessed using a radiolabeled GAPDH cDNA probe.
as acetyl CoA carboxylase and fatty acid synthase, genes
encoding enzymes involved in fatty acid synthesis, were
also increased in homocysteine-treated HepG2 cells
(data not shown). Similar patterns of gene induction
were also observed in HASMCs and HUVECs exposed
to homocysteine (data not shown). Addition of cyclo-
heximide to cells exposed to homocysteine did not
inhibit the induction of these genes (data not shown), a
finding consistent with a mechanism involving the acti-
vation of existing precursor SREBPs (28, 29).
Induction of IPP isomerase gene expression by ER stress.
HepG2 cells were treated with ER stress-inducing agents,
including tunicamycin, DTT, β-mercaptoethanol, and
the calcium ionophore, A23187, and Northern blot
analysis was used to examine changes in IPP isomerase
gene expression. To varying degrees, all ER stress agents
tested induced the expression of IPP isomerase, com-
pared with untreated cells (Figure 5). Similar results were
also observed for HASMCs and HUVECs treated with
ER stress agents (data not shown).
Overexpression of GRP78/BiP prevents the induction of
SREBP-1 and IPP isomerase genes by homocysteine. Overex-
pression of GRP78/BiP has been reported to protect
cells from ER stress (39, 40). Stably transfected cells
overexpressing GRP78/BiP were generated to assess
whether blocking homocysteine-induced ER stress
attenuated the expression of SREBP-1 and IPP iso-
merase. As shown in Figure 6a, the GRP78/BiP-overex-
pressing cells exhibited a threefold increase in
GRP78/BiP protein levels, compared with wild-type or
vector-transfected cells. Furthermore, GRP78/BiP was
localized to the ER at a much greater intensity, com-
pared with wild-type cells (Figure 6b). When treated
with homocysteine, the steady-state mRNA levels of
SREBP-1 and IPP isomerase were dramatically
decreased in the GRP78/BiP-overexpressing cells, com-
pared with vector-transfected (Figure 6c) or wild-type
cells (data not shown). These findings indicate that
overexpression of GRP78/BiP inhibits the induction of
SREBP-1 and IPP isomerase gene expression by homo-
cysteine and suggests that ER stress plays an important
role in the activation of genes responsible for choles-
terol/triglyceride biosynthesis.
Effect of homocysteine on cellular levels of cholesterol. To
determine whether the homocysteine-mediated induc-
tion of genes responsible for cholesterol biosynthesis is
associated with a corresponding increase in intracellu-
lar cholesterol, HUVECs, HASMCs, and HepG2 cells
were cultured in the absence or presence of either
homocysteine or cysteine for 24 and 48 hours, and total
cholesterol was determined. Incubation with 1 or 5
mM homocysteine increased cellular cholesterol in
HepG2 and HASMCs (Figure 7). In contrast, choles-
terol levels were unchanged in HUVECs, despite
increased expression of SREBP-1 and genes encoding
enzymes in the cholesterol biosynthetic pathway. Incu-
bation with cysteine did not influence levels of choles-
terol in any of the cell types (data not shown).
Effect of homocysteine on LDL uptake. In addition to their
effects on cholesterol/triglyceride biosynthesis, the
SREBPs also regulate LDL-receptor expression and
activity (28, 29). To explore the effect of homocysteine
on cholesterol uptake via the LDL receptor, we meas-
ured the ability of cultured cells treated with homocys-
teine to bind and internalize fluorescently labeled LDL
(Figure 8). Our results indicate that after incubation
with homocysteine, HASMCs maintained their ability
to endocytose LDL while HepG2 cells showed
enhanced LDL uptake. These results suggest that
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Figure 6
Overexpression of GRP78/BiP prevents the increase in steady-state
mRNA levels of SREBP-1 and IPP isomerase by homocysteine. (a)
Immunoblot analysis of GRP78/BiP and GRP94 in wild-type
(T24/83), vector-transfected (T24/83-pcDNA), or GRP78/BiP–over-
expressing (T24/83-GRP78) cells. Total protein lysates (40 µg/lane)
were separated on 10% SDS-polyacrylamide gels under reducing con-
ditions and either stained with Coomassie blue (upper panel) or
immunostained with an anti-KDEL mAb. (b) Immunolocalization of
GRP78/BiP in the ER of wild-type or GRP78/BiP–overexpressing
T24/83 cells. Cells grown on glass coverslips were fixed, permeabi-
lized, and immunostained with an anti-GRP78/BiP polyclonal Ab.
×800. (c) Northern blot analysis of the steady-state mRNA levels of
SREBP-1 and IPP isomerase in vector-transfected (T24/83-pcDNA)
or GRP78/BiP–overexpressing (T24/83-GRP78) cells cultured in the
absence or presence of 1 mM homocysteine for the indicated time
periods. Total RNA (10 µg/lane) was size fractionated by agarose-
gel electrophoresis, transferred to nylon membranes, and subjected
to blot hybridization using radiolabeled cDNA probes encoding
human SREBP-1 or IPP isomerase. Control for equivalent RNA load-
ing was assessed using a radiolabeled GAPDH cDNA probe.
upregulation of the cholesterol/triglyceride biosyn-
thetic pathway in HASMCs and HepG2 cells does not
result from impaired LDL uptake. In contrast,
HUVECs treated with homocysteine showed a signifi-
cant decrease in LDL uptake, which may explain why
these cells do not accumulate cholesterol and triglyc-
erides when incubated with homocysteine.
Cholesterol levels in mice with diet-induced hyperhomocys-
teinemia. To determine the effect of hyperhomocys-
teinemia on lipid metabolism in vivo, we measured
cholesterol and triglycerides in the livers and plasmas
of CBS+/+ and CBS+/– mice fed control or hyperhomo-
cysteinemic diets for 10 to 20 weeks. Compared with
age-matched mice fed control diet, CBS+/+ mice fed the
high-methionine/low-folate diet had markedly elevat-
ed levels of hepatic cholesterol and triglycerides (Table
1). Hepatic cholesterol also was elevated modestly in
CBS+/+ mice fed the high-methionine diet. Compared
with CBS+/+ mice fed the same diets, CBS+/– mice exhib-
ited similar hepatic triglyceride levels and slightly
increased hepatic cholesterol levels. Plasma cholesterol
levels tended to be elevated in CBS+/+ and CBS+/– mice
fed the high-methionine/low-folate diet compared with
mice fed control diet, but these differences did not
reach statistical significance. No differences in plasma
triglycerides were detected between groups. Histologi-
cal analysis of liver sections from CBS+/+ and CBS+/–
mice fed high-methionine/low-folate diet revealed that
their hepatocytes were engorged with lipid vesicles (Fig-
ure 9). All mice with diet-induced hyperhomocysteine-
mia appeared normal and their body weights were sim-
ilar to those of mice fed control diets.
VLDL-triglyceride secretion rate in mice fed control or hyper-
homocysteinemic diet. To assess whether the accumulation
of hepatic cholesterol and triglycerides were due to
impaired lipid export, VLDL-triglyceride secretion rate
was determined by injecting CBS+/+ mice that had been
fasted overnight with Triton WR1339. Because Triton
WR1339 blocks conversion of VLDL to LDL, the result-
ing increase in plasma triglyceride and cholesterol con-
centrations reflect hepatic secretion of VLDL in the
absence of LDL uptake (34). Figure 10 shows that the
hepatic triglyceride secretion rate was significantly high-
er in CBS+/+ mice fed hyperhomocysteinemic diets, com-
pared with CBS+/+ mice fed control diet. Furthermore, the
triglyceride secretion rate was highest in mice fed the very
high-methionine/low-folate diet, which produced the
highest levels of plasma total homocysteine (334 ± 100
µM). Cholesterol secretion rate was also significantly ele-
vated in these mice. These results suggest that accumu-
lation of hepatic cholesterol and triglycerides in hyper-
homocysteinemia is related to increased biosynthesis and
uptake rather than decreased hepatic export of VLDL.
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Figure 7
Homocysteine increases intracellular total cholesterol in cultured human
cells. HUVECs, HASMCs, and HepG2 cells were incubated for 48 hours
in media containing 0, 0.2, 1, or 5 mM homocysteine. Cells were washed
in PBS, harvested in 0.2 M NaOH, and lipids extracted as described in
Methods. Total cholesterol was normalized for protein content, and val-
ues were expressed as a percentage versus cells treated in the absence of
homocysteine. Data are presented as the mean ± SD from three separate
experiments. AP < 0.05 between control and homocysteine-treated cells.
Table 1
Comparison of cholesterol and triglyceride levels in the livers and plasmas of CBS+/+ and CBS+/– mice fed control or hyperhomocysteinemic diets
Plasma Liver
Genotype DietA homocysteineB cholesterol triglycerides cholesterolC triglyceridesC
(µM) (mM) (mM) (mg/mg protein) (mg/mg protein)
CBS+/+
Control 2.5 (0.9) 0.91 (0.49) 4.8 (0.8) 0.018 (0.006) 0.10 (0.02)
HM 8.8 (4.5) 0.66 (0.30) 5.7 (1.6) 0.027 (0.002)D 0.11 (0.01)
HMLF 60 (61) 1.56 (0.40) 6.7 (1.5) 0.16 (0.04)D 0.69 (0.31)D
CBS+/–
Control 6.2 (3.8) 0.93 (0.45) 6.0 (1.0) 0.026 (0.003)E 0.11 (0.03)
HM 27 (18) 0.63 (0.27) 5.5 (1.6) 0.025 (0.001) 0.12 (0.02)
HMLF 48 (63) 1.41 (0.37) 6.7 (1.5) 0.33 (0.02)D 0.39 (0.06)D
AMice were fed control, HM, or HMLF diets for 10 weeks. BAll data are expressed as the mean ± SD (n = 4 to 8 mice/group). CLiver cholesterol and triglyceride
concentrations are normalized to the total protein content of the tissue. DP < 0.05 between the indicated values and the corresponding controls. EP < 0.05
between CBS+/– and CBS+/+ controls. HM, high-methionine; HMLF, high-methionine/low-folate.
Hyperhomocysteinemic mice have increased hepatic mRNA
levels of GADD153, SREBP-1, and the LDL receptor. To
determine whether hepatic cholesterol and triglyceride
accumulation in hyperhomocysteinemic mice is associ-
ated with ER stress and activation of the UPR, we
probed total RNA isolated from the livers of CBS+/+ mice
fed control or hyperhomocysteinemic diets for
GADD153 gene expression (Figure 11), which is a direct
indicator of ER stress (41, 42). Northern blot analysis
demonstrated that steady-state mRNA levels of
GADD153 were elevated 6.7-fold in mice
fed high-methionine diet and 11.4-fold
in mice fed high-methionine/low-folate
diet for 2 weeks, compared with control
mice (P < 0.05). This result suggests that
hyperhomocysteinemia causes ER stress
and UPR activation in vivo.
Northern blot analysis indicated that the steady-
state mRNA levels of SREBP-1 and the LDL receptor
were also significantly increased (P < 0.05) in the livers
of CBS+/+ mice with diet-induced hyperhomocysteine-
mia, compared with control mice (Figure 11). This
result is consistent with our in vitro findings and sug-
gests that a combination of increased endogenous
cholesterol/triglyceride production and uptake lead to
hepatic lipid accumulation in mice having diet-
induced hyperhomocysteinemia.
Discussion
The present study provides novel evidence that homo-
cysteine-induced ER stress enhances lipid biosynthesis
and uptake through activation of the SREBPs and like-
ly explains the development and progression of hepatic
steatosis in hyperhomocysteinemia. Specifically, we
have demonstrated that homocysteine-induced ER
stress (a) activates the UPR leading to increased expres-
sion of GRP78/BiP and GADD153, (b) induces prote-
olytic cleavage of SREBP-1 and -2, (c) enhances expres-
sion of genes responsible for cholesterol/triglyceride
biosynthesis and uptake, and (d) increases total choles-
terol without decreasing LDL uptake in cultured hepa-
tocytes and smooth muscle cells. Consistent with our in
vitro findings, a significant increase in GADD153,
SREBP-1, and LDL receptor-gene expression, as well as
the accumulation of cholesterol and triglycerides, were
observed in livers of mice having diet-induced hyperho-
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Figure 8
Effect of homocysteine on LDL uptake in HUVECs, HASMCs, and
HepG2. Cells treated in the absence or presence of 5 mM homocysteine
for 8 hours were washed with PBS followed by incubation for an addi-
tional 2 hours at 37°C in media containing 10 µg/ml BODIPY FL LDL.
After washing with PBS, cells were fixed, and LDL binding/uptake was
detected by fluorescence microscopy. ×375.
Figure 9
Hepatic morphology of CBS+/+ and CBS+/– mice
fed control diet or high-methionine/low-folate
diet. CBS+/+ mice fed control (a) or high-methio-
nine/low-folate diet (c) for 20 weeks. CBS+/– mice
fed control (b) or high-methionine/low-folate
diet (d) for 16 weeks. The hepatocytes from mice
fed the high-methionine/low-folate diet (c and d)
are enlarged, multinucleated, and contain exten-
sive microvesicular and macrovesicular lipid with
no apparent fibrosis or necrosis. Hematoxylin
and eosin staining. ×400.
mocysteinemia. The additional observation that VLDL-
triglyceride secretion rates were significantly elevated in
hyperhomocysteinemic mice suggests that hepatic
steatosis is not due to impaired lipid export, but instead
results from increased lipid biosynthesis and uptake.
Although previous studies have demonstrated hepatic
steatosis in homozygous CBS–/– mice having severe
hyperhomocysteinemia (12), our findings provide direct
evidence that hepatic steatosis can occur in CBS+/+ and
CBS+/– mice having diet-induced hyperhomocysteine-
mia and further highlight the importance of diet as a
major contributor to the pathophysiological outcome
of hyperhomocysteinemia.
Increased dietary methionine or deficiencies of folic
acid and vitamin B6 and/or vitamin B12 can lead to
hyperhomocysteinemia in humans (43–45) and animals
(32, 35, 46, 47). However, the mechanisms by which ele-
vated levels of homocysteine promote the pathological
changes associated with hyperhomocysteinemia are
poorly understood. Because the highly reactive thiol
group of homocysteine is readily oxidized in plasma to
form reactive oxygen species, it has been suggested that
homocysteine exerts its cytotoxic effect through a mech-
anism involving oxidative damage (15–17, 48, 49). How-
ever, the oxidative stress hypothesis fails to explain why
cysteine, which is present in plasma in concentrations
25- to 30-fold higher than those of total homocysteine
and is readily oxidized, is not usually considered to be a
risk factor for cardiovascular disease (20). In fact, mark-
ers of oxidative stress have not been observed in cul-
tured human cells exposed to homocysteine (21–24) or
in the livers of hyperhomocysteinemic mice (49). How-
ever, given that homocysteine decreases the expression
of a wide range of antioxidant enzymes (21) and impairs
the activity of glutathione peroxidase (50), homocys-
teine may indirectly enhance oxidative damage in cer-
tain cells or tissues by decreasing cellular antioxidant
potential (20, 51). An additional hypothesis is that cel-
lular dysfunction is caused by elevation of intracellular
concentrations of homocysteine itself and that elevated
plasma total homocysteine is a marker of increased
intracellular homocysteine. To increase intracellular
homocysteine levels in some cultured cells, we and oth-
ers have applied exogenous homocysteine in concentra-
tions up to 5 mM (21–24). Though significantly higher
than the pathophysiological range of plasma total
homocysteine, these concentrations of homocysteine
do not impair cell viability and only transiently increase
intracellular levels twofold to sixfold (21, 22). Unlike
cysteine, homocysteine causes specific intracellular
effects including ER stress (21–24), decreased bioavail-
ability of nitric oxide (50), and increased protein dam-
age caused by homocysteinylation (18, 19).
We found that hepatic ER stress and UPR activation
were evident when mice were fed hyperhomocysteinemic
diets for 2 weeks. It is well established that agents and/or
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Figure 10
VLDL-triglyceride secretion rates in CBS+/+ mice fed control or hyper-
homocysteinemic diets. CBS+/+ mice were fed a control diet, a high-
methionine diet (HM), a high-methionine/low-folate diet (HMLF),
or a very high-methionine/low-folate diet (SHH) for 2 weeks. Plasma
VLDL-triglyceride levels were determined in mice 0, 2, and 4 hours
after Triton WR1339 injection. Hepatic VLDL-triglyceride secretion
rate was calculated from the slope of the curve. Data are presented
as the mean ± SD (n = 4 mice/group). Mean total plasma homocys-
teine concentration for mice on the SHH diet was 334 ± 100 µM.
AP < 0.05 between control and mice having hyperhomocysteinemia.
Figure 11
Increased steady-state mRNA levels of GADD153, SREBP-1, and the
LDL receptor in the livers of mice having hyperhomocysteinemia.
CBS+/+ mice were fed a control diet (C), a high-methionine diet (HM),
or a combination high-methionine/low-folate diet (HMLF). After 2
weeks, the animals were sacrificed and tissues harvested. Total RNA
(10 µg/lane) isolated from the livers of two randomly selected ani-
mals from each group (n = 5) was examined by Northern blot analy-
sis using radiolabeled cDNA probes encoding human GADD153,
SREBP-1, or LDL receptor. Control for equivalent RNA loading was
assessed using a radiolabeled GAPDH cDNA probe.
conditions that adversely affect ER function activate the
UPR, resulting in increased expression of GRP78/BiP,
GRP94 (52–54), GADD153 (41, 42), and activation of
the ER membrane-bound transcription factor, ATF6
(55). Recent studies have indicated that the UPR regu-
lates lipid biosynthesis in yeast (25, 26) and dolichol
biosynthesis, which is part of the cholesterol biosynthe-
sis pathway, in human fibroblasts (27). It is likely that
the UPR coordinates the synthesis of ER chaperones as
well as ER membrane components to increase the fold-
ing capacity and the space required to accommodate the
accumulation of unfolded proteins. Our findings sug-
gest that activation of the UPR by homocysteine pro-
motes the overproduction of ER lipid components,
including cholesterol and triglycerides, resulting in the
accumulation of lipids within affected cells. It follows
that by blocking or minimizing ER stress, it may be pos-
sible to attenuate the induction of lipid biosynthesis. In
support of this concept, we observed that stable overex-
pression of GRP78/BiP, which protects cells from agents
or conditions known to cause ER stress (39, 40), inhibits
homocysteine-induced expression of genes involved in
cholesterol biosynthesis in cultured human cells.
Despite an increase in VLDL-triglyceride secretion rate,
hyperhomocysteinemic mice did not have significantly
increased levels of plasma cholesterol or triglycerides.
These observations suggest that hepatic steatosis in
hyperhomocysteinemia does not result from impaired
VLDL export, but instead is due to increased lipid biosyn-
thesis coupled with inappropriately enhanced uptake of
LDL by liver and perhaps other tissues. These findings are
consistent with previous studies demonstrating increased
hepatic lipid biosynthesis and VLDL secretion in trans-
genic mice that overexpress fully active, nuclear SREBP-
1a (56, 57). These mice also develop severe hepatic steato-
sis, but maintain normal plasma lipid profiles as a result
of SREBP-induced LDL receptor activity. The localized
accumulation of lipid in tissues, such as liver, that are sen-
sitive to ER stress provides a plausible explanation as to
the prevalence of hepatic steatosis in hyperhomocys-
teinemic patients having relatively normal serum lipid
profiles. Furthermore, our results may explain why, with
few exceptions (58), epidemiological studies have not
shown a correlation between elevated plasma levels of
total homocysteine and increased plasma levels of cho-
lesterol and/or triglycerides.
Under normal circumstances, SREBP expression and
activity are regulated by the SREBP cleavage-activation
protein (SCAP) according to the lipid requirements of the
cell (59, 60). Homocysteine appears to circumvent this
feedback mechanism, maintaining cells in a sterol-
starved state despite the accumulation of lipids.
Although we do not currently understand how homo-
cysteine dysregulates SREBP activation, the mechanism
appears to involve homocysteine-induced ER stress.
Recently it has been shown that ER stress induces cleav-
age of membrane-bound ATF6 by the same proteases
that activate SREBP (designated S1P and S2P) (61). In
addition, the ER stress-induced processing of ATF6 does
not require SCAP (61). These results raise the possibility
that, in hepatocytes and smooth muscle cells, homocys-
teine-induced ER stress abrogates the requirement for
SCAP and activates both ATF6 and SREBP by a similar
mechanism. Identifying the components in the homo-
cysteine-signaling cascade that ultimately regulate acti-
vation of SREBP and disrupt its feedback control system
will further enhance our understanding of the link
between hyperhomocysteinemia and the molecular
events that result in increased lipid biosynthesis.
In conclusion, our data support a mechanism by which
cells that are sensitive to elevated intracellular levels of
homocysteine experience ER stress that leads to the acti-
vation and dysregulation of the endogenous sterol
response pathway. In mice with diet-induced hyperho-
mocysteinemia this results in hepatic steatosis, a condi-
tion observed in virtually all CBS-deficient patients hav-
ing severe hyperhomocysteinemia. Additional studies are
now underway to determine whether this ER stress mech-
anism contributes to the development and progression
of atherosclerotic lesions in hyperhomocysteinemia.
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